Physician-researchers have raised concerns that there are inconsistencies between the five reference guides, or compendia, that the Centers for Medicare and Medicaid Services uses to determine which drugs it will reimburse for off-label uses in cancer care.

Source: Researchers question process for reviewing coverage of 'off label' cancer drug use


David Cottle

UBB Owner & Administrator